Jan Dreher
Bayer (Germany)(DE)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Treatment of Major Depression, Psychiatric care and mental health services, Biomedical and Chemical Research, Receptor Mechanisms and Signaling
Most-Cited Works
- → Target 2035 – update on the quest for a probe for every protein(2021)78 cited
- → Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation(2010)66 cited
- → 2-Anilino-4-(benzimidazol-2-yl)pyrimidines – A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines(2012)50 cited
- → Target 2035 – an update on private sector contributions(2023)17 cited
- → xMaP—An Interpretable Alignment-Free Four-Dimensional Quantitative Structure–Activity Relationship Technique Based on Molecular Surface Properties and Conformer Ensembles(2017)16 cited
- → QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids(2010)10 cited
- → BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor(2022)7 cited
- → Psychopharmakotherapie griffbereit(2018)4 cited
- → ChemInform Abstract: 2‐Anilino‐4‐(benzimidazol‐2‐yl)pyrimidines — A Multikinase Inhibitor Scaffold with Antiproliferative Activity Toward Cancer Cell Lines.(2012)1 cited